Welcome to our dedicated page for Altimmune SEC filings (Ticker: ALT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Altimmune, Inc. (ALT) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a Nasdaq-listed biopharmaceutical issuer. Altimmune’s common stock, par value $0.0001 per share, is registered on The Nasdaq Global Market under the symbol ALT, and its Exchange Act and Securities Act filings offer detailed insight into its clinical, financial and corporate activities.
For a late clinical-stage company focused on peptide-based therapeutics for liver, metabolic and cardiometabolic diseases, periodic reports and current reports are particularly important. Forms such as the annual report on Form 10-K and quarterly reports on Form 10-Q (when available) describe Altimmune’s business, risk factors, clinical programs and financial condition. Current reports on Form 8-K document material events, including clinical trial results for pemvidutide, Fast Track and Breakthrough Therapy designations, equity distribution agreements for at-the-market offerings, amendments to loan facilities, executive transitions and annual meeting outcomes.
Altimmune’s proxy materials, such as the definitive proxy statement on Form DEF 14A, outline governance matters, board composition, executive compensation and items submitted to stockholders at the annual meeting. These filings help investors understand how the company is overseen and how leadership is incentivized as it advances pemvidutide through Phase 2 and prepares for planned Phase 3 development in MASH.
On Stock Titan, Altimmune filings are updated in near real time as new documents are posted to EDGAR. AI-powered tools summarize lengthy filings, highlight key terms in agreements such as loan amendments or equity distribution arrangements, and make it easier to locate information on topics like clinical milestones, financing capacity or voting results. Users can also review disclosures related to capital structure, including at-the-market programs and term loan facilities, to see how Altimmune funds its liver and cardiometabolic disease pipeline.
Altimmune Chief Scientific Officer Scot M. Roberts reported multiple equity transactions involving company stock. On January 30, 2026, 9,275 restricted stock units (RSUs) vested and were settled into common shares, with 2,859 shares surrendered to Altimmune to cover taxes. On January 31, 2026, he acquired 5,567 shares through the 2019 Employee Stock Purchase Plan at $3.07 per share, based on 85% of the August 1, 2025 closing price. On February 2, 2026, a further 7,775 RSUs vested into common stock and 2,329 shares were surrendered for taxes. After these transactions, he directly held 112,824 shares of Altimmune common stock.
Altimmune, Inc. has scheduled its 2026 Annual Meeting of Stockholders for Thursday, April 16, 2026, aligning its meeting timing with the typical second-quarter calendar for companies with a December 31 fiscal year-end. Stockholders of record at the close of business on Friday, March 13, 2026 will be entitled to receive notice of and vote at the meeting.
The exact time and location will be detailed in the company’s proxy statement, and the meeting is expected to be held virtually, similar to prior years. Stockholder proposals under Rule 14a-8 must reach the Company’s Secretary at its Gaithersburg, Maryland headquarters by February 13, 2026 to be considered for inclusion in the proxy materials.
Under Altimmune’s bylaws, any other stockholder proposals or director nominations for consideration at the 2026 Annual Meeting must also be received by the Corporate Secretary no later than February 13, 2026 and must meet bylaw requirements. Stockholders intending to solicit proxies for alternative director nominees under the universal proxy rules must provide the required notice by February 15, 2026 in accordance with the bylaws and Rule 14a-19.
Altimmune director Vipin K. Garg reported multiple equity transactions. On January 30, 2026, 26,775 Restricted Stock Units converted into an equal number of common shares at $0 exercise price as part of a vesting event. In connection with this vesting, 11,632 shares were surrendered to Altimmune to cover taxes at a price of $5.60 per share. On January 31, 2026, Garg acquired 6,926 additional common shares through the company’s 2019 Employee Stock Purchase Plan at $3.07 per share, equal to 85% of the August 1, 2025 closing price. After these transactions, Garg directly held 424,519 shares of common stock and 26,775 RSUs.
Altimmune, Inc.'s Chief Business Officer, Jordt Raymond M, increased his direct ownership through the company’s employee stock purchase plan. On January 31, 2026, he acquired 4,571 shares of common stock at a price of $3.07 per share under the 2019 Employee Stock Purchase Plan, tied to the purchase period from August 1, 2025 through January 31, 2026. Following this automatic plan-based purchase, he directly holds 70,107 shares of Altimmune common stock.
Altimmune Inc received an updated Schedule 13G/A from The Vanguard Group, which reports beneficial ownership of 9,491,159 shares of Altimmune common stock, representing 9.09% of the outstanding class.
Vanguard reports no sole voting or dispositive power, with shared voting power over 744,210 shares and shared dispositive power over all 9,491,159 shares. Following an internal realignment on January 12, 2026, certain Vanguard subsidiaries are expected to report holdings separately. Vanguard states the shares are held in the ordinary course of business, not to change or influence control, and that its clients have the economic rights to dividends and sale proceeds, with no single client owning more than 5%.
Altimmune, Inc.’s Chief Business Officer, Raymond M. Jordt, reported routine equity compensation activity. On January 27, 2026, 15,850 Restricted Stock Units (RSUs) were converted into an equal number of common shares at $0 per share. A separate transaction shows 4,229 common shares were surrendered at $6.18 per share to Altimmune solely to cover taxes associated with the RSU vesting. Following these transactions, Jordt directly owns 65,536 shares of common stock and 47,550 RSUs, which each represent a contingent right to receive one common share. The RSUs vest in substantially equal annual installments over four years following January 27, 2025, subject to continued service, and have no expiration date.
Altimmune, Inc. director Vipin K. Garg reported RSU vesting and related share movements. On January 27, 2026, 41,200 Restricted Stock Units converted into the same number of Altimmune common shares at a stated price of $0 per share.
To cover taxes on the RSU vesting, 17,898 common shares were surrendered to the issuer at a price of $6.18 per share. After these transactions, Garg directly held 402,450 Altimmune common shares and 123,600 RSUs, which vest in substantially equal annual installments over four years following January 27, 2025.
Altimmune Chief Scientific Officer Scot Roberts reported equity compensation activity involving company stock. On January 27, 2026, he converted 15,850 Restricted Stock Units into an equal number of Altimmune common shares at $0 per share, reflecting standard RSU settlement. In a related tax withholding step, 4,748 shares were surrendered to Altimmune at $6.18 per share to cover taxes due on the vesting. Following these transactions, Roberts directly owned 95,395 shares of common stock and 47,550 RSUs, which each represent a right to receive one share of common stock as they vest over time.
Altimmune, Inc. entered into a securities purchase agreement with a new institutional investor for a registered direct offering of common stock and pre-funded warrants expected to raise approximately $75 million in gross proceeds.
The investor will purchase 12,397,920 shares of common stock and pre-funded warrants to buy up to 4,647,534 additional shares at a nominal $0.001 exercise price per warrant. The pre-funded warrants are immediately exercisable, do not expire, and are subject to a beneficial ownership cap starting at 9.99%, which can be increased up to 19.99% with notice. Directors and executive officers agreed to 30-day lock-up restrictions after closing.
Altimmune, Inc. is conducting a registered direct offering of 12,397,920 shares of common stock and pre-funded warrants to purchase up to 4,647,534 additional shares, for a total offering price of $75,000,000. The company expects net proceeds of about $70.4 million after fees and expenses.
Altimmune plans to use the cash, together with existing resources, to advance clinical development and manufacturing for its lead drug pemvidutide, including preparation for a Phase 3 trial in MASH and potential commercial launch, and for general corporate purposes. Management currently expects available funds to support operations through the end of 2027, subject to development plans.